DE202022003132U1 - Genetische Modifikation von Säugerzellen zur Verleihung von Resistenz gegen CSF1R-Antagonisten - Google Patents

Genetische Modifikation von Säugerzellen zur Verleihung von Resistenz gegen CSF1R-Antagonisten Download PDF

Info

Publication number
DE202022003132U1
DE202022003132U1 DE202022003132.7U DE202022003132U DE202022003132U1 DE 202022003132 U1 DE202022003132 U1 DE 202022003132U1 DE 202022003132 U DE202022003132 U DE 202022003132U DE 202022003132 U1 DE202022003132 U1 DE 202022003132U1
Authority
DE
Germany
Prior art keywords
csf1r
modified
human cell
until
modified human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE202022003132.7U
Other languages
German (de)
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California, San Diego
Original Assignee
University of California Berkeley
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California, San Diego filed Critical University of California Berkeley
Publication of DE202022003132U1 publication Critical patent/DE202022003132U1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
DE202022003132.7U 2021-04-01 2022-04-01 Genetische Modifikation von Säugerzellen zur Verleihung von Resistenz gegen CSF1R-Antagonisten Active DE202022003132U1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163169578P 2021-04-01 2021-04-01
US63/169,578 2021-04-01
US202163236951P 2021-08-25 2021-08-25
US63/236,951 2021-08-25

Publications (1)

Publication Number Publication Date
DE202022003132U1 true DE202022003132U1 (de) 2025-02-17

Family

ID=83456857

Family Applications (4)

Application Number Title Priority Date Filing Date
DE202022003132.7U Active DE202022003132U1 (de) 2021-04-01 2022-04-01 Genetische Modifikation von Säugerzellen zur Verleihung von Resistenz gegen CSF1R-Antagonisten
DE202022002866.0U Active DE202022002866U1 (de) 2021-04-01 2022-04-01 Genetische Modifikation von Säugetierzellen zur Verleihung von Resistenz gegen CSF1R-Antagonisten
DE112022000079.1T Withdrawn DE112022000079T5 (de) 2021-04-01 2022-04-01 Genetische Modifikation von Säugetierzellen zur Verleihung von Resistenz gegen CSF1R-Antagonisten
DE202022003066.5U Withdrawn - After Issue DE202022003066U1 (de) 2021-04-01 2022-04-01 Genetische Modifikation von Säugerzellen zur Verleihung von Resistent gegen CSF1R-Antagonisten

Family Applications After (3)

Application Number Title Priority Date Filing Date
DE202022002866.0U Active DE202022002866U1 (de) 2021-04-01 2022-04-01 Genetische Modifikation von Säugetierzellen zur Verleihung von Resistenz gegen CSF1R-Antagonisten
DE112022000079.1T Withdrawn DE112022000079T5 (de) 2021-04-01 2022-04-01 Genetische Modifikation von Säugetierzellen zur Verleihung von Resistenz gegen CSF1R-Antagonisten
DE202022003066.5U Withdrawn - After Issue DE202022003066U1 (de) 2021-04-01 2022-04-01 Genetische Modifikation von Säugerzellen zur Verleihung von Resistent gegen CSF1R-Antagonisten

Country Status (8)

Country Link
US (3) US20230248775A1 (cg-RX-API-DMAC7.html)
EP (1) EP4314003A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024513003A (cg-RX-API-DMAC7.html)
AU (1) AU2022252407A1 (cg-RX-API-DMAC7.html)
CA (1) CA3215311A1 (cg-RX-API-DMAC7.html)
DE (4) DE202022003132U1 (cg-RX-API-DMAC7.html)
GB (1) GB2612467B (cg-RX-API-DMAC7.html)
WO (1) WO2022212897A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12612599B2 (en) 2018-09-10 2026-04-28 Savanna Biotherapeutics, Inc. Compositions and methods for microglia replacement therapy
DE202022003132U1 (de) * 2021-04-01 2025-02-17 The Regents Of The University Of California Genetische Modifikation von Säugerzellen zur Verleihung von Resistenz gegen CSF1R-Antagonisten

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1576139A4 (en) * 2002-11-26 2007-06-20 Cold Spring Harbor Lab INTERACTIVE PROTEINS AND ASSOCIATED METHODS OF DEP-1 RECEPTOR PROTEIN-TYROSINE PHOSPHATASE
US9044503B2 (en) 2004-08-27 2015-06-02 University Of Kentucky Research Foundation Amyloid peptide inactivating enzyme to treat alzheimer's disease peripherally
WO2006069203A2 (en) 2004-12-22 2006-06-29 California Institute Of Technology Methods for proteomic profiling using non-natural amino acids
WO2009089635A1 (en) 2008-01-16 2009-07-23 Neurodyn, Inc. Treating neurodegenerative diseases with progranulin (pgrn)
KR20100054711A (ko) 2008-11-14 2010-05-25 메디포스트(주) 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물
EP2424976B1 (en) 2009-04-28 2013-07-31 Life & Brain GmbH Method for obtaining human microglial precursor cells from pluripotent stem cells
US8765117B2 (en) 2009-06-10 2014-07-01 The General Hospital Corporation Generation of vascularized human heart tissue and uses thereof
CA2818253A1 (en) 2010-11-16 2012-05-24 Denis G. Kay Method for increasing neprilysin expression and activity
CA2831609C (en) 2011-03-30 2019-06-11 Cellular Dynamics International, Inc. Priming of pluripotent stem cells for neural differentiation
EP3092305B1 (en) 2014-01-09 2023-08-02 Kyushu University, National University Corporation Method of producing microglial cells
US10081792B2 (en) 2014-12-31 2018-09-25 Wisconsin Alumni Research Foundation Derivation of human microglia from pluripotent stem cells
CA2972598C (en) 2014-12-31 2024-03-12 Wisconsin Alumni Research Foundation Human pluripotent stem cell-based models for predictive developmental neural toxicity
JP6774952B2 (ja) 2015-01-16 2020-10-28 エージェンシー フォー サイエンス, テクノロジー アンド リサーチ 多能性幹細胞のマクロファージへの分化
US10626372B1 (en) 2015-01-26 2020-04-21 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
WO2016210313A1 (en) 2015-06-24 2016-12-29 Whitehead Institute For Biomedical Research Culture medium for generating microglia from pluripotent stem cells and related methods
CA3016575A1 (en) 2016-03-03 2017-09-08 New York Stem Cell Foundation, Inc. Microglia derived from pluripotent stem cells and methods of making and using the same
WO2017223199A1 (en) 2016-06-22 2017-12-28 Xcell Biosciences, Inc. Methods for increasing cell culture transfection efficiency and cellular reprogramming
CN109963940A (zh) 2016-09-02 2019-07-02 宝生物工程株式会社 从多能干细胞获得小胶质细胞的方法
CA3038690A1 (en) 2016-10-05 2018-04-12 FUJIFILM Cellular Dynamics, Inc. Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
CN110621774A (zh) 2016-10-14 2019-12-27 儿童医疗中心有限公司 用于治疗中枢神经系统疾病和病症的组合物和方法
WO2018160496A1 (en) 2017-02-28 2018-09-07 The Regents Of The University Of California Differentiation and use of human microglia-like cells from pluripotent stem cells and hematopoietic progenitors
WO2019118951A2 (en) 2017-12-15 2019-06-20 Duke University Compositions and methods of enhancing the homing and/or engraftment of hematopoietic cells in the central nervous system
US12171764B2 (en) * 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
WO2020033791A1 (en) * 2018-08-09 2020-02-13 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
US12612599B2 (en) * 2018-09-10 2026-04-28 Savanna Biotherapeutics, Inc. Compositions and methods for microglia replacement therapy
CN113166219A (zh) 2018-09-28 2021-07-23 纪念斯隆-凯特琳癌症中心 干细胞衍生的人小神经胶质细胞、制备方法及使用方法
US12419915B2 (en) 2019-03-13 2025-09-23 The Broad Institute, Inc. Microglial progenitors for regeneration of functional microglia in the central nervous system and therapeutics uses thereof
WO2020232512A1 (en) 2019-05-22 2020-11-26 The Council Of The Queensland Institute Of Medical Research Microglial cells and methods of use thereof
WO2020252477A1 (en) 2019-06-14 2020-12-17 FUJIFILM Cellular Dynamics, Inc. Methods for the production of multiple lineages from induced pluripotent stem cells using charged surfaces
EP4010361A4 (en) 2019-08-06 2023-08-09 Children's Medical Center Corporation METHODS AND COMPOSITIONS FOR RESTORING MICROGLIA
TWI799733B (zh) 2019-08-26 2023-04-21 臺北榮民總醫院 一種從體細胞製備誘導性多能幹細胞之方法
WO2021221879A1 (en) 2020-05-01 2021-11-04 Albert Einstein College Of Medicine Compositions and methods for using transplanted microglia as a vehicle for widespread delivery of cells and other biologic agents to the brain
US20240117431A1 (en) 2020-06-02 2024-04-11 The Regents Of The University Of California Stem-cell based biomarker discovery
GB202011871D0 (en) 2020-07-30 2020-09-16 Cambridge Entpr Ltd Composition and method
EP4204544A4 (en) 2020-08-25 2024-10-30 University Health Network COMPOSITIONS AND METHODS FOR GENERATING HUMAN YOLK SAC-TYPE HEMATOPOIETIC CELLS
DE202022003132U1 (de) 2021-04-01 2025-02-17 The Regents Of The University Of California Genetische Modifikation von Säugerzellen zur Verleihung von Resistenz gegen CSF1R-Antagonisten

Also Published As

Publication number Publication date
US20250002920A1 (en) 2025-01-02
GB2612467A (en) 2023-05-03
EP4314003A1 (en) 2024-02-07
AU2022252407A1 (en) 2023-10-12
DE202022003066U1 (de) 2024-09-19
EP4314003A4 (en) 2025-03-12
DE202022002866U1 (de) 2024-03-20
US20230203500A1 (en) 2023-06-29
DE112022000079T5 (de) 2023-06-15
AU2022252407A9 (en) 2023-10-26
WO2022212897A1 (en) 2022-10-06
GB202219686D0 (en) 2023-02-08
JP2024513003A (ja) 2024-03-21
US20230248775A1 (en) 2023-08-10
GB2612467B (en) 2025-11-19
CA3215311A1 (en) 2022-10-06
US12421517B2 (en) 2025-09-23

Similar Documents

Publication Publication Date Title
Kaiser et al. Tmem119-EGFP and Tmem119-CreERT2 transgenic mice for labeling and manipulating microglia
Elmore et al. CSF1 receptor signaling is necessary for microglia viability, which unmasks a cell that rapidly repopulates the microglia-depleted adult brain
Pákáski et al. Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease
DE112012000404T5 (de) Modulatoren von IL-12 und/oder IL-23 zur Prävention oder Behandlung des Morbus Alzheimer
DE69233643T2 (de) Verwendung von Antizytokin-enthaltenden pharmazeutischen Zusammensetzungen zur Therapie von multipler Sklerose
Yaksh et al. Role of meningeal mast cells in intrathecal morphine evoked granuloma formation
Lowenstein et al. Olig3 regulates early cerebellar development
Britschgi et al. Deficiency of terminal complement pathway inhibitor promotes neuronal tau pathology and degeneration in mice
US20250002920A1 (en) Genetic modification of mammalian cells to confer resistance to csf1r antagonists
Denny et al. Nalfurafine reduces neuroinflammation and drives remyelination in models of CNS demyelinating disease
IL292467A (en) Treatment of hematopoietic cell cancers using genetically engineered t cells targeting cd70
Zhu et al. Neuroprotective effects of human umbilical cord-derived mesenchymal stem cells from different donors on spinal cord injury in mice
DE60306896T2 (de) Verwendung von niedermolekularen verbindungen zur herstellung eines medikaments zur behandlung von durch mutation p53-vermittelten erkrankungen
EP3296316B1 (de) Peptide zur behandlung und frühdiagnose von morbus alzheimer und anderer tauopathien
EP1171587A1 (de) Peptid aus antigen muc-1 zur auslösung einer imminreaktion gegen tumorzellen
DE112018002302B4 (de) Chimärer Antigenrezeptor von Anti-Human-CD19-Antigen und dessen Anwendung
IL283885B2 (en) CXCR7 inhibitors for cancer treatment
DE3884853T2 (de) Angiogenininhibitoren.
DE10259619A1 (de) Verwendung einer TRPM8 aktivierenden Substanz zur Tumorbehandlung
DE102008047128A1 (de) Verwendung von cis-Imidazolinen, insbesondere Nutlinen, zur Behandlung von chemoresistenten Krebserkrankungen
DE112020003610T5 (de) Neue anwendungen von phenothiazinen oder ihren verbindungen ähnlicher struktur in der pharmazeutik
CN117580871A (zh) 哺乳动物细胞的基因修饰赋予对csf1r拮抗剂的抗性
DE10142996A1 (de) Verwendung von Wirkstoffen mit mu-Opioid-Rezeptor agonistischer Wirkung als Kombinationsarzneimittel zur Krebsbehandlung
Konttinen et al. Microglial amyloid beta clearance is driven by PIEZO1 channels
Taupin Stem Cell Therapy for Alzheimer's

Legal Events

Date Code Title Description
R207 Utility model specification
R150 Utility model maintained after payment of first maintenance fee after three years